Enanta to Present Zelicapavir Data at IDWeek 2026
Enanta Pharmaceuticals said it will present data for zelicapavir, an oral, once-daily N-protein inhibitor in development for respiratory syncytial virus, at IDWeek 2026.
Enanta Pharmaceuticals said it will present data for zelicapavir, an oral, once-daily N-protein inhibitor in development for respiratory syncytial virus, at IDWeek 2026.